Recurrent Adult Soft Tissue Sarcoma Recruiting Phase 2 Trials for Durvalumab (DB11714)

IndicationStatusPhase
DBCOND0028931 (Recurrent Adult Soft Tissue Sarcoma)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03317457Durvalumab and Tremelimumab Compared to Doxorubicin in Patients With Advanced or Metastatic Soft Tissue SarcomaTreatment